SecBot SecBot
Insider Cluster (2 insiders) ·Filed May 4, 2026

TRDA

Entrada Therapeutics, Inc.
BEARISH
Impact 5/10
Horizonweeks Processed6mo ago
Insider cluster: 2 insiders, $629K total
Actionable Insight ▼ Bearish

Two top executives selling in the same window, with one exercising and immediately flipping options, is a cautionary signal. Monitor for upcoming clinical data readouts, earnings, or corporate events that may have prompted the selling.

DirectionBearish
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$15.75
T+0 close · May 4, 2026 · via day close
Latest settled
−56.89%
T+60 · $6.79
Vs SPY
−60.37%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $15.75entry
  2. T+1 · 7mo ago +1.78%α +0.39% · $16.03
  3. T+5 · 6mo ago −54.79%α −56.78% · $7.12
  4. T+20 · 6mo ago −58.22%α −62.43% · $6.58
  5. T+60 · 4mo ago −56.89%α −60.37% · $6.79
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two top executives at Entrada Therapeutics sold a combined $629K in open-market sales over a 7-day window, with President & COO Dowden also exercising and immediately selling derivative shares. The total sales represent ~0.11% of market cap, a modest but notable cluster involving both the COO and R&D President, suggesting insider caution ahead of potential catalysts or data readouts.

Key Financial Metrics

Direction
selling
Total Value
$629.0K
Insiders
2

Key Facts

  • President & COO Nathan Dowden sold 15,000 shares at $15.33 for $230K on May 4, 2026
  • President of R&D Sethuraman Natarajan sold 25,907 shares at $15.39 for $399K on May 4, 2026
  • Dowden also exercised 15,000 derivative shares at $1.74 ($26,100 cost) and immediately sold them
  • Total open-market sales: $629K, representing ~0.11% of $563M market cap
  • Cluster occurred in a 7-day window ending May 4, 2026
  • No insider purchases were reported in this cluster

Financial Impact

Total insider sales of $629K, ~0.11% of market cap

insider ownership

Risk Factors

  • Insider selling by both COO and R&D President may signal lack of near-term catalysts or concerns about upcoming data
  • Derivative exercise and immediate sale suggests monetization rather than conviction holding
  • Stock has appreciated significantly in recent months, increasing risk of mean reversion

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-TRDA-1777937131163

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026